Plan to Submit Application for Accelerated Approval for Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024Expects to Begin Enrollment in Phase 3 Confirmatory Trial, RAMP 301, of Avutometinib and Defactinib in LGSOC in Q4 2023Presented Additional Patient Subgroup Data for the...

Related Keywords

United States , Ryan Porter , Elisa Buffington , Dan Paterson , Pancreatic Cancer Action Network Pan , Chugai Pharmaceutical Co Ltd , Development Collaboration , Foundation Inc , Drug Administration , Head Of Regulatory Affairs , Corporate Communications , Patient Impact , World Ovarian Cancer Coalition , Patient Impact Advisory Committee , International Conference On Molecular , Exchange Commission , European Network Of Gynaecological Oncological Trial , Amgen , Ovarian Cancer Foundation , Raf And Mek Program , Submit Application , Accelerated Approval , Recurrent Low Grade Serous Ovarian Cancer , Begin Enrollment , Additional Patient Subgroup Data , Defactinib Showing Promising Levels , Prior Therapies Including After Poor Response , Into Synergistic Discovery , Genfleet Therapeutics , Advance New Programs Targeting , Verastem Oncology , Chief Executive Officer , Grade Serous Ovarian Cancer , European Network , Gynaecological Oncological Trial , Annual Global Meeting , Pinternational Gynecologic Cancer Society , Impact Advisory Committee , Cancer Foundation , Cure Our Ovarian Cancer , Molecular Targets , Cancer Therapeutics , Pancreatic Cancer Action Network , Mike Crowther , Chief Commercial , Business Strategy Officer , David Mitchell , Senior Vice President , Regulatory Affairs , Dan Calkins , Chief Financial Officer , Vice President , Breakthrough Therapy , Annual Report , Consolidated Statements ,